American Center for Cures Act of 2005

Bill: 109-s-2104
Sponsor: Sen. Lieberman, Joseph I. [D-CT]
Introduced: 2005-12-14 in the Senate
Policy area: Health
Subjects: Advice and consent of the Senate
Armed Forces and National Security
Arts, Culture, Religion
Biological warfare
Biomedical engineering
Clinical trials
Commerce
Communication in medicine
Congress
Crime and Law Enforcement
Curricula
Cytology
Data banks
Department of Health and Human Services
Diseases
Drug industry
Economics and Public Finance
Education
Epidemics
Executive reorganization
Federal advisory bodies
Federal aid to education
Federal aid to research
Genetic research
Government Operations and Politics
Government publicity
Governmental investigations
Graduate education
Higher education
Human experimentation in medicine
Immunology and vaccination
Informed consent (Medical law)
Intellectual property
Law
Marketing
Medical education
Medical ethics
Medical laboratories
Medical libraries
Medical personnel
Medical research
Medical statistics
Medical tests
Minorities
Minority health
Nanotechnology
National Institutes of Health (NIH)
Patents
Pharmaceutical research
Presidential appointments
Preventive medicine
Research and development facilities
Research centers
Science, Technology, Communications
Scientific education
Small business
Technology transfer
Terrorism
Vaccines

Summary:
action_date: 2005-12-14
text: 
American Center for Cures Act of 2005 - Amends the Public Health Service Act to establish within the National Institutes of Health (NIH) an American Center for Cures to promote translational research to speed the development of effective therapies, diagnostics, and cures.
 
Establishes a Cures Council to help advise and direct the Center's translational research efforts.
 
Authorizes the Center's Director (the Director of Cures) to establish Federally Funded Research and Development Centers to serve as research sites.
 
Establishes within the Center a Health Advanced Research Projects Agency to advance the development and deployment of critical health products. Authorizes the Agency to flexibly fund projects.
 
Requires the Director of Cures to establish a series of Centralized Institutional Review Boards to serve as human subject safety and well being custodians for multi-institutional clinical trials that are funded by public dollars.
 
Requires the Director of NIH to commission the Institute of Medicine to study the rules that protect patient safety and anonymity with respect to clinical research.
 
Establishes an Office of Bioscientific Enterprise Development (OBED) and transfers to it the Small Business Innovation Research and Small Business Technology Transfer programs. Requires OBED to partner grantees with potential purchasers of products. 
 
Establishes an Office of Technology Transfer (OTT) and transfers to it appropriate NIH functions. Requires OTT to establish: (1) an Office of Rapid Access to Intervention Development to accelerate the process from laboratory to clinic; and (2) a program that cultivates industry interest in NIH-funded research.
 
Establishes an Office of Intramural Risk Opportunity and Mapping to oversee the intramural research programs of NIH.
 
Requires the Center for Biotechnology Information to develop new computational methods to aid in the processing of genomic data.
 
Provides for the construction of a clinical study registry and results database.


Legislative actions:
action_date: 2005-12-14
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S13583-13589)
action_date: 2005-12-14
text: Sponsor introductory remarks on measure. (CR S13577-13583)
action_date: 2005-12-14
text: Introduced in Senate